Immunai is on a mission to fully map the immune system to better detect, diagnose and treat disease by advancing personalized medicine through a comprehensive understanding of the immune system. Its proprietary database and machine learning algorithms map incoming data to hundreds of cell types and states by highlighting novel elements. The team is composed of genomics, machine learning, bioinformatics, immunology, and software engineering experts, is headquartered in New York City, and has offices in San Francisco and Tel Aviv. The company has raised $20M in its seed round led by Viola Group and TLV Partners.

Founded by (from left to right): Luis Voloch (CTO) and Noam Solomon (CEO)

Go To Site


Join Our Mailing ListSign up to receive regular updates from our blog and news about Viola